PURPOSE: To evaluate the effects on 1-year event-free survival (EFS) and overall survival (OS) of combining motexafin and gadolinium (MGd), a potent radiosensitizer, with daily fractionated radiation therapy in children with newly diagnosed intrinsic pontine gliomas. METHODS AND MATERIALS: Patients with newly diagnosed intrinsic pontine glioma were treated with MGd daily for 5 consecutive days each week, for a total of 30 doses. Patients received a 5- to 10-min intravenous bolus of MGd, 4.4 mg/kg/day, given 2 to 5 h prior to standard dose irradiation. Radiation therapy was administered at a daily dose of 1.8 Gy for 30 treatments over 6 weeks. The total dose was 54 Gy. RESULTS: Sixty eligible children received MGd daily, concurrent with 6 weeks of radiation therapy. The estimated 1-year EFS was 18%±5%, and the estimated 1-year OS was 53%±6.5%. The most common grade 3 to 4 toxicities were lymphopenia, transient elevation of liver transaminases, and hypertension. CONCLUSIONS: Compared to historical controls, the addition of MGd to a standard 6-week course of radiation did not improve the survival of pediatric patients with newly diagnosed intrinsic pontine gliomas.
PURPOSE: To evaluate the effects on 1-year event-free survival (EFS) and overall survival (OS) of combining motexafin and gadolinium (MGd), a potent radiosensitizer, with daily fractionated radiation therapy in children with newly diagnosed intrinsic pontine gliomas. METHODS AND MATERIALS: Patients with newly diagnosed intrinsic pontine glioma were treated with MGd daily for 5 consecutive days each week, for a total of 30 doses. Patients received a 5- to 10-min intravenous bolus of MGd, 4.4 mg/kg/day, given 2 to 5 h prior to standard dose irradiation. Radiation therapy was administered at a daily dose of 1.8 Gy for 30 treatments over 6 weeks. The total dose was 54 Gy. RESULTS: Sixty eligible children received MGd daily, concurrent with 6 weeks of radiation therapy. The estimated 1-year EFS was 18%±5%, and the estimated 1-year OS was 53%±6.5%. The most common grade 3 to 4 toxicities were lymphopenia, transient elevation of liver transaminases, and hypertension. CONCLUSIONS: Compared to historical controls, the addition of MGd to a standard 6-week course of radiation did not improve the survival of pediatric patients with newly diagnosed intrinsic pontine gliomas.
Authors: J Allen; J Siffert; B Donahue; A Nirenberg; R Jakacki; P Robertson; R DaRosso; L Thoron; M Rosovsky; R Pinto Journal: Cancer Date: 1999-09-15 Impact factor: 6.860
Authors: Darren Magda; Philip Lecane; Richard A Miller; Cheryl Lepp; Dale Miles; Mimi Mesfin; John E Biaglow; Vincent V Ho; Danny Chawannakul; Shailender Nagpal; Mazen W Karaman; Joseph G Hacia Journal: Cancer Res Date: 2005-05-01 Impact factor: 12.701
Authors: L R Mandell; R Kadota; C Freeman; E C Douglass; J Fontanesi; M E Cohen; E Kovnar; P Burger; R A Sanford; J Kepner; H Friedman; L E Kun Journal: Int J Radiat Oncol Biol Phys Date: 1999-03-15 Impact factor: 7.038
Authors: Philip S Lecane; Mazen W Karaman; Mint Sirisawad; Louie Naumovski; Richard A Miller; Joseph G Hacia; Darren Magda Journal: Cancer Res Date: 2005-12-15 Impact factor: 12.701
Authors: Ilker Y Eyüpoglu; Eric Hahnen; Rolf Buslei; Florian A Siebzehnrübl; Nicolai E Savaskan; Mike Lüders; Christian Tränkle; Wolfgang Wick; Michael Weller; Rudolf Fahlbusch; Ingmar Blümcke Journal: J Neurochem Date: 2005-05 Impact factor: 5.372
Authors: Valerie Bernier-Chastagner; Jacques Grill; Francois Doz; Serge Bracard; Jean Claude Gentet; A Marie-Cardine; E Luporsi; G Margueritte; O Lejars; V Laithier; F Mechinaud; F Millot; C Kalifa; Pascal Chastagner Journal: Cancer Date: 2005-12-15 Impact factor: 6.860
Authors: R J Packer; J M Boyett; R A Zimmerman; A L Albright; A M Kaplan; L B Rorke; M T Selch; J M Cherlow; J L Finlay; W M Wara Journal: Cancer Date: 1994-09-15 Impact factor: 6.860
Authors: Lindsay B Kilburn; Mehmet Kocak; Patricia Baxter; Tina Young Poussaint; Arnold C Paulino; Christine McIntyre; Annabelle Lemenuel-Diot; Christine Lopez-Diaz; Larry Kun; Murali Chintagumpala; Jack M Su; Alberto Broniscer; Justin N Baker; Eugene I Hwang; Maryam Fouladi; James M Boyett; Susan M Blaney Journal: Pediatr Blood Cancer Date: 2017-11-01 Impact factor: 3.167
Authors: Amar Gajjar; Roger J Packer; N K Foreman; Kenneth Cohen; Daphne Haas-Kogan; Thomas E Merchant Journal: Pediatr Blood Cancer Date: 2012-12-19 Impact factor: 3.167
Authors: Amar Gajjar; Daniel C Bowers; Matthias A Karajannis; Sarah Leary; Hendrik Witt; Nicholas G Gottardo Journal: J Clin Oncol Date: 2015-08-24 Impact factor: 44.544
Authors: Zoltan Patay; Thomas E Merchant; Rosa Nguyen; Christopher R Pierson; Arzu Onar-Thomas; Alberto Broniscer Journal: Int J Radiat Oncol Biol Phys Date: 2017-08-24 Impact factor: 7.038